dc.contributor.author |
Rodrigues-Soares, Fernanda |
|
dc.contributor.author |
Penas-Lledo, Eva M. |
|
dc.contributor.author |
Tarazona-Santos, Eduardo |
|
dc.contributor.author |
Sosa-Macias, Martha |
|
dc.contributor.author |
Teran, Enrique |
|
dc.contributor.author |
Lopez-Lopez, Marisol |
|
dc.contributor.author |
Rodeiro, Idania |
|
dc.contributor.author |
Moya, Graciela E. |
|
dc.contributor.author |
Calzadilla, Luis R. |
|
dc.contributor.author |
Ramirez-Roa, Ronald |
|
dc.contributor.author |
Grazina, Manuela |
|
dc.contributor.author |
Estevez-Carrizo, Francisco E. |
|
dc.contributor.author |
Barrantes, Ramiro |
|
dc.contributor.author |
Llerena, Adrian |
|
dc.date.accessioned |
2019-08-08T15:23:45Z |
|
dc.date.available |
2019-08-08T15:23:45Z |
|
dc.date.issued |
2019 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12866/7134 |
|
dc.description.abstract |
We present the distribution of CYP2D6, CYP2C9 and CYP2C19 variants and predicted phenotypes in 33 native and admixed populations from Ibero-America (n>6,000) in the context of genetic ancestry (n=3,387). Continental ancestries are the major determinants of frequencies of the increased-activity allele CYP2C19*17 and CYP2C19 gUMs (negatively associated with Native American ancestry), decreased-activity alleles CYP2D6*41 and CYP2C9*2 (positively associated with European ancestry), and decreased-activity alleles CYP2D6*17 and CYP2D6*29 (positively associated with African ancestry). For the rare alleles CYP2C9*2 and CYPC19*17, European admixture accounts for their presence in Native American populations, but rare alleles CYP2D6*5 (null-activity), CYP2D6-multiplication alleles (increased activity) and CYP2C9*3 (decreased-activity) were present in the pre-Columbian Americas. The study of a broad spectrum of Native American populations from different ethno-linguistic groups shows how autochthonous diversity shaped the distribution of pharmaco-alleles and give insights on the prevalence of clinically relevant phenotypes associated with drugs such as paroxetine, tamoxifen, warfarin and clopidogrel. |
en_US |
dc.language.iso |
eng |
|
dc.publisher |
Wiley |
|
dc.relation.ispartofseries |
Clinical Pharmacology and Therapeutics |
|
dc.rights |
info:eu-repo/semantics/restrictedAccess |
|
dc.rights.uri |
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es |
|
dc.subject |
Ancestry |
en_US |
dc.subject |
Pharmacogenetics |
en_US |
dc.subject |
Native American |
en_US |
dc.subject |
CYP |
en_US |
dc.subject |
Latin American |
en_US |
dc.title |
Genomic ancestry, CYP2D6, CYP2C9 and CYP2C19 among Latin-Americans |
en_US |
dc.type |
info:eu-repo/semantics/article |
|
dc.identifier.doi |
https://doi.org/10.1002/cpt.1598 |
|
dc.subject.ocde |
https://purl.org/pe-repo/ocde/ford#3.01.05 |
|
dc.relation.issn |
1532-6535 |
|